Xinfeng capsule attenuates ankylosing spondylitis by downregulating YTHDC1-mediated m

Background: Ankylosing spondylitis (AS) is a chronic inflammatory disorder predominantly affecting the sacroiliac and spinal joints. Emerging evidence indicates that N Objective: This study aimed to investigate whether XFC mitigates AS inflammation by regulating the IL-17/NF-κB pathway via m Methods: Core therapeutic targets were identified by integrating network pharmacology with RNA-sequencing data. The direct interaction between YTHDC1 and LINC01579 was validated using RNA pull-down and dual-luciferase reporter assays. To identify the functional m6A sites, site-directed mutagenesis of two putative m6A motifs (MUT1 and MUT2) in LINC01579 was performed, and the effects of YTHDC1 knockdown were assessed. An Results: Bioinformatics and network pharmacology analysis identified LINC01579 as a core gene in AS inflammation and YTHDC1 as an upstream regulator of LINC01579 m Conclusion: XFC alleviates AS progression by inhibiting YTHDC1-mediated m6A modification of LINC01579, which prevents its degradation and subsequently dampens IL-17/NF-κB pathway activation. These findings highlight a potential epigenetic mechanism underlying the therapeutic effects of XFC in AS.